There are no issues in the first cohort that are negative. The early results are fantastic and suggest huge possibility in CHMs CAR-T therapy.
There are issues that that will be worked through, specifically the relationship with mmp2 expression, however, it is plain to see that this is not a problem, or a negative result. Quite simply, IF they already knew the mechanism of action, they would not need to do trials. Working to discover how this works is both admirable and commercially valuable.
Your attempt to frame these issues in a negative light without any real qualification is simply anti-academic downramping, trolling or scaremongering. This kind of behaviour usually signifies personal or economic desperation and or motivation.
It's quite clear that the CHMs ticker fluctuates between speclative buying, accumulation and paranoid / impatient selling. Not a mystery at all, as this is how every other stock and commodity the history of commercial markets operate.
I strongly trust Jennifer Chows answers and also the results and explanations in the company announcements.
All IMHO.
CHM Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)